Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.39M shares outstanding
USKairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer.
Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016.
The company's operations are headquartered in Los Angeles, California.
John S. Yu
Chief Executive Officer, Chairman & Secretary
Neil A. Bhowmick
Chief Scientific Officer
Ramachandran Murali
Vice President of Research & Development
Douglas W. Samuelson
Chief Financial Officer
Employees
4
Country
US
Sector
Healthcare
Website
kairospharma.com
Loading congressional disclosures…
based on 3.39M shares outstanding
US30d Avg
945.83K
60d Avg
502.22K
90d Avg
623.30K
